Medical News

RSS

HeartWare prices public offering of convertible senior notes due 2017

HeartWare International, Inc. announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") yesterday.

10 Dec 2010

North Castle completes sale of Atkins

North Castle Partners, a leading investor in small-cap consumer companies focused on health, wellness and active living, announced today that the firm and its co-investors have completed the sale of Atkins Nutritional Holdings, Inc..

10 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

First Edition: December 10, 2010

In today's health policy headlines, reports about the Obama administration lawyer charged with defending the health law as well as the latest action in this lame duck Congress.

10 Dec 2010

FDA approves Mylan's generic Adalat CC Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Bayer's Adalat® CC Tablets, a treatment for hypertension.

10 Dec 2010

Official guidelines for diagnosis, treatment and management of food allergies released

A collaborative, government-led effort to guide and standardize diagnosis, treatment and management of food allergies has resulted in the release of an official set of recommendations for physicians.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (http://www.uspto.gov).

10 Dec 2010

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Helicopter emergency medical services can be a life saver for patients needing immediate care. But, according to a University of Cincinnati study, the process of activating them often delays treatment beyond recommended times.

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

TSX accepts QLT's notice of normal course issuer bid

QLT Inc. announced today that the Toronto Stock Exchange has accepted the notice of QLT's intention to make a normal course issuer bid in the open market through the facilities of the TSX and/or the NASDAQ Stock Market, which was originally announced on December 8, 2010.

10 Dec 2010

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Elekta K.K., a wholly owned subsidiary of Elekta AB, has entered into a sales and marketing agreement with Toshiba Medical Systems Corporation in Japan.

From Elekta 10 Dec 2010

Social activities most promising in prevention of depression among older adults

Interventions focused on social activities significantly decrease depressive symptoms among older adults. This is the results from a recent study.

10 Dec 2010

Alliance of Specialty Medicine calls for new, permanent Medicare reimbursement formula

The Alliance of Specialty Medicine (Alliance) today called on Congress to permanently fix Medicare's Sustainable Growth Rate (SGR) after lawmakers once again passed a temporary fix, thereby postponing unprecedented reimbursement cuts to Medicare doctors until 2012.

10 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

STENTYS S.A., which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has begun the international APPOSITION III study of its self-apposing stent, with 50 patients already enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events at 12 months post-procedure.

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

Too often, mental health patients have problems accessing or paying for their prescription drugs under Medicaid. The results — longer hospital stays and more emergency room visits — are hard on patients and costly for the entire health care system, a new study finds.

10 Dec 2010

AvMed to optimize Member Services call center operation with Panviva SupportPoint

AvMed Health Plans announced today that it has chosen Panviva SupportPoint, a world-wide leader in Business Process Guidance (BPG) systems, to optimize its Member Services call center operation and drive even higher levels of member satisfaction.

10 Dec 2010

Medical News

HeartWare prices public offering of convertible senior notes due 2017

North Castle completes sale of Atkins

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

First Edition: December 10, 2010

FDA approves Mylan's generic Adalat CC Tablets ANDA

Official guidelines for diagnosis, treatment and management of food allergies released

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

TSX accepts QLT's notice of normal course issuer bid

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Social activities most promising in prevention of depression among older adults

Alliance of Specialty Medicine calls for new, permanent Medicare reimbursement formula

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

AvMed to optimize Member Services call center operation with Panviva SupportPoint

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News